Product Description

Generic Name: Bevacizumab Injection Trade Name: Pusintin Strengths：100mg（4ml）/ vial Storage： Store and distribute refrigerated at 2°C to 8°C in the original carton and protect from light. Do not freeze and  shake the vial or carton.  Shelf Life：24 months Approval Time (China) ：2021/11/30 Approved indications (China) ：Metastatic Colorectal Cancer （mCRC）; Advanced, Recurrent or Metastatic Non– Small Cell Lung Cancer （NSCLC） Indications under Application (China) : Recurrent glioblastoma （rGBM）; Epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (OC); Cervical cancer （CC）; hepatocellular carcinoma （HCC） Originator：Avastin（Roche） Marketing status and approved indications ：Bevacizumab was first approved by FDA in 2004 and approved by EMA in 2005. It was marketed in China for the treatment of metastatic colorectal cancer in 2010. It was also approved by NMPA for the treatment of non-squamous non-small cell lung cancer in 2015 and glioblastoma in 2020. Treatment for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, cervical cancer and hepatocellular carcinoma have been approved in 2021. Up to now, many indications for solid tumor have been approved, including colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, liver cancer (combined with PD-L1) and so on